Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
-edge for Ce in bauxites using transition-edge sensors; Implications for Ti-rich geological samplesLi, W.*; Yamada, Shinya*; Hashimoto, Tadashi; Okumura, Takuma*; Hayakawa, Ryota*; Nitta, Kiyofumi*; Sekizawa, Oki*; Suga, Hiroki*; Uruga, Tomoya*; Ichinohe, Yuto*; et al.
Analytica Chimica Acta, 1240, p.340755_1 - 340755_9, 2023/02
Times Cited Count：2 Percentile：31.9(Chemistry, Analytical)no abstracts in English
Okumura, Takuma*; Azuma, Toshiyuki*; Bennet, D. A.*; Caradonna, P.*; Chiu, I.-H.*; Doriese, W. B.*; Durkin, M. S.*; Fowler, J. W.*; Gard, J. D.*; Hashimoto, Tadashi; et al.
IEEE Transactions on Applied Superconductivity, 31(5), p.2101704_1 - 2101704_4, 2021/08
Times Cited Count：1 Percentile：11.15(Engineering, Electrical & Electronic)A superconducting transition-edge sensor (TES) microcalorimeter is an ideal X-ray detector for experiments at accelerator facilities because of good energy resolution and high efficiency. To study the performance of the TES detector with a high-intensity pulsed charged-particle beam, we measured X-ray spectra with a pulsed muon beam at the Japan Proton Accelerator Research Complex (J-PARC) in Japan. We found substantial temporal shifts of the X-ray energy correlated with the arrival time of the pulsed muon beam, which was reasonably explained by pulse pileup due to the incidence of energetic particles from the initial pulsed beam.
X raysOkumura, Takuma*; Azuma, Toshiyuki*; Bennet, D. A.*; Caradonna, P.*; Chiu, I. H.*; Doriese, W. B.*; Durkin, M. S.*; Fowler, J. W.*; Gard, J. D.*; Hashimoto, Tadashi; et al.
Physical Review Letters, 127(5), p.053001_1 - 053001_7, 2021/07
Times Cited Count：13 Percentile：79.44(Physics, Multidisciplinary)We observed electronic X rays emitted from muonic iron atoms using a superconducting transition-edge-type sensor microcalorimeter. The energy resolution of 5.2 eV in FWHM allowed us to observe the asymmetric broad profile of the electronic characteristic 
and 
X rays together with the hypersatellite X rays around 6 keV. This signature reflects the time-dependent screening of the nuclear charge by the negative muon and the 
-shell electrons, accompanied by electron side-feeding. Assisted by a simulation, this data clearly reveals the electronic - and -shell hole production and their temporal evolution during the muon cascade process.
Lu for radioimmunotherapyWatanabe, Satoshi; Hashimoto, Kazuyuki; Watanabe, Shigeki; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko
Journal of Radioanalytical and Nuclear Chemistry, 303(1), p.935 - 940, 2015/01
Times Cited Count：11 Percentile：67.3(Chemistry, Analytical)
spp. under the ISS environmental conditions for performing exposure experiments of microbes in the Tanpopo missionKawaguchi, Yuko*; Yang, Y.*; Kawashiri, Narutoshi*; Shiraishi, Keisuke*; Takasu, Masako*; Narumi, Issey*; Sato, Katsuya; Hashimoto, Hirofumi*; Nakagawa, Kazumichi*; Tanigawa, Yoshiaki*; et al.
Origins of Life and Evolution of Biospheres, 43(4-5), p.411 - 428, 2013/10
Times Cited Count：41 Percentile：80.34(Biology)Fujii, Hirofumi*; Hara, Kazuhiko*; Hashimoto, Shugo*; Ito, Fumiaki*; Kakuno, Hidekazu*; Kim, S.*; Kochiyama, Mami; Nagamine, Kanetada*; Suzuki, Atsuto*; Takada, Yoshihisa*; et al.
Progress of Theoretical and Experimental Physics (Internet), 2013(7), p.073C01_1 - 073C01_20, 2013/07
Times Cited Count：26 Percentile：76.73(Physics, Multidisciplinary)
to extreme environmentsHorikawa, Daiki*; Yamaguchi, Ayami*; Sakashita, Tetsuya; Tanaka, Daisuke*; Hamada, Nobuyuki*; Yukuhiro, Fumiko*; Kuwahara, Hirokazu*; Kunieda, Takekazu*; Watanabe, Masahiko*; Nakahara, Yuichi*; et al.
Astrobiology, 12(4), p.283 - 289, 2012/04
Times Cited Count：23 Percentile：68.76(Astronomy & Astrophysics)We examined the hatchability of hydrated and anhydrobiotic eggs of the tardigrade to hatch after ionizing irradiation (helium ions), extremely low and high temperatures, and high vacuum. Anhydrobiotic eggs (50% lethal dose; 1690 Gy) were substantially more radioresistant than hydrated ones (50% lethal dose; 509 Gy). Anhydrobiotic eggs also have a broader temperature resistance compared with hydrated ones. Over 70% of the anhydrobiotic eggs treated at high and low temperatures, but all of the hydrated eggs failed to hatch. After exposure to high vacuum conditions, the hatchability of the anhydrobiotic eggs was comparable to that of untreated control eggs.
-diketone and methylphenylphenanthroline carboxamideHasegawa, Yuko*; Tamaki, Sayaka*; Yajima, Hirofumi*; Hashimoto, Bunji*; Yaita, Tsuyoshi
Talanta, 85(3), p.1543 - 1548, 2011/09
Times Cited Count：38 Percentile：77.53(Chemistry, Analytical)Lu for radioimmunotherapyWatanabe, Satoshi; Hashimoto, Kazuyuki; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko
JAEA-Review 2010-065, JAEA Takasaki Annual Report 2009, P. 109, 2011/01
no abstracts in English
Watanabe, Satoshi; Hashimoto, Kazuyuki; Watanabe, Shigeki; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko
JAEA-Review 2009-041, JAEA Takasaki Annual Report 2008, P. 109, 2009/12
no abstracts in English
Re-MAG3-conjugated bisphosphonate (Re-MAG3-HBP), an agent for treatment of painful bone metastasesOgawa, Kazuma*; Mukai, Takahiro*; Kawai, Keiichi*; Takamura, Norito*; Hanaoka, Hirofumi*; Hashimoto, Kazuyuki; Shiba, Kazuhiro*; Mori, Hirofumi*; Saji, Hideo*
European Journal of Nuclear Medicine and Molecular Imaging, 36(1), p.115 - 121, 2009/01
Times Cited Count：23 Percentile：57.81(Radiology, Nuclear Medicine & Medical Imaging)We have developed a Re-MAG3 complex-conjugated bisphosphonate (Re-MAG3-HBP) for the treatment of painful bone metastases. We assumed competitive inhibitors of protein binding to be useful for procuring a favorable biodistribution of Re-MAG3-HBP because it has been reported that the concurrent administration of 
Tc-MAG3 and drugs with high affinity for serum protein enhanced total clearance and tissue distribution. The protein binding of Re-MAG3-HBP in a human serum albumin solution was significantly decreased by the addition of ceftriaxone. In the biodistribution experiments, pretreatment with ceftriaxone enhanced the clearance of the radioactivity of Re-MAG3-HBP in blood and nontarget tissues but had no effect on accumulation in bone. The findings suggested that the use of protein-binding competitive inhibitors would be effective in improving the pharmacokinetics of radiopharmaceuticals with high affinity for serum protein.
Re]Organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levelsUehara, Tomoya*; Koike, Miho*; Nakata, Hideo*; Hanaoka, Hirofumi*; Iida, Yasuhiko*; Hashimoto, Kazuyuki; Akizawa, Hiromichi*; Endo, Keigo*; Arano, Yasushi*
Bioconjugate Chemistry, 18(1), p.190 - 198, 2007/01
Times Cited Count：20 Percentile：55.24(Biochemical Research Methods)Renal localization of radiolabeled antibody fragments constitutes a problem in targeted imaging and radiotherapy. To estimate the applicability of the molecular design to metallic radionuclides, [Re]tricarbonyl(cyclopentadienylcarbonate)rhenium ([Re]CpTR-COOH) was conjugated with maleoyl-glycyl-lysine to prepare [Re]CpTR-GK. The cleavage of the glycyl-lysine linkage of the compound generates a glycine conjugate of [Re]CpTR-Gly. [Re]CpTR-GK was conjugated to thiolated Fab fragments to prepare [Re]CpTR-GK-Fab. The biodistribution of radioactivity after injection of [Re]CpTR-GK-Fab was compared with that of [Re]CpTR-Fab. [Re]CpTR-GK-Fab exhibited significantly lower renal radioactivity levels than did [Re]CpTR-Fab. The analysis of urine samples collected for 6 h postinjection of [Re]CpTR-GK-Fab showed that [Re]CpTR-Gly was the major radiometabolite. In tumor-bearing mice, [Re]CpTR-GK-Fab significantly reduced renal radioactivity levels without impairing the radioactivity levels in tumor. These findings indicate that the molecular design of radioparmaceuticals labeled with metallic radionuclides can be useful by using a radiometal chelate of high inertness and by designing a radiometabolite of high urinary excretion when released from antibody fragments following cleavage of a glycyl-lysine linkage. This study also indicates that a change in chemical structure of a radiolabel attached to a glycyl-lysine linkage significantly affected enzymes involved in the hydrolysis reaction.
Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal modelOgawa, Kazuma*; Mukai, Takahiro*; Asano, Daigo*; Kawashima, Hidekazu*; Kinuya, Seigo*; Shiba, Kazuhiro*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*
Journal of Nuclear Medicine, 48(1), p.122 - 127, 2007/01
We developed a highly stable rhenium-186 (Re)-MAG3 complex-conjugated bisphosphonate, (Re-MAG3-HBP), for the treatment of painful bone metastases. This agent showed a superior biodistribution as a bone-seeking agent in normal mice when compared with Re-HEDP. In this study, we evaluated the therapeutic effects of Re-MAG3-HBP using an animal model of bone metastasis. In the rats treated with Re-HEDP, tumor growth was comparable to that in untreated rats. In contrast, when Re-MAG3-HBP was administered, tumor growth was significantly inhibited. Allodynia induced by bone metastasis was attenuated by treatment with Re-MAG3-HBP or Re-HEDP, but Re-MAG3-HBP tended to be more effective. These results indicate that Re-MAG3-HBP could be useful as a therapeutic agent for the palliation of metastatic bone pain.
Ogawa, Kazuma*; Mukai, Takahiro*; Arano, Yasushi*; Ono, Masahiro*; Hanaoka, Hirofumi*; Ishino, Seigo*; Hashimoto, Kazuyuki; Nishimura, Hiroshi*; Saji, Hideo*
Bioconjugate Chemistry, 16(4), p.751 - 757, 2005/07
Times Cited Count：61 Percentile：86.86(Biochemical Research Methods)Rhenium-186-1-hydroxyethylidene-1,1-diphosphonate (Re-HEDP) has been used for the palliation of metastatic bone pain. Delayed blood clearance and high gastric uptake of radioactivity have been observed upon injection, due to the instability of Re-HEDP in vivo. In this study, on the basis of the concept of bifunctional radiopharmaceuticals, we designed a stable Re-mercaptoacetylglycylglycylglycine (MAG3) complex-conjugated bisphosphonate (Re-MAG3-HBP). After purification by HPLC, Re-MAG3-HBP was synthesized with a radiochemical purity of over 95%. In biodistribution experiments, the radioactivity level ofRe-MAG3-HBP in bone was significantly higher than that of Re-HEDP. Blood clearance of Re-MAG3-HBP was faster than that of Re-HEDP. In addition, the gastric accumulation of Re-MAG3-HBP radioactivity was lower than that of Re-HEDP. In conclusion, Re-MAG3-HBP is expected to be a useful radiopharmaceutical for the palliation of metastatic bone pain.
Ogawa, Kazuma*; Mukai, Takahiro*; Arano, Yasushi*; Hanaoka, Hirofumi*; Hashimoto, Kazuyuki; Nishimura, Hiroshi*; Saji, Hideo*
Journal of Labelled Compounds and Radiopharmaceuticals, 47(11), p.753 - 761, 2004/11
Times Cited Count：28 Percentile：61.65(Biochemical Research Methods)no abstracts in English
Re-labeled bisphosphonate in a rat model of bone metastasisOgawa, Kazuma*; Mukai, Takahiro*; Asano, Daigo*; Kawashima, Hidekazu*; Hashimoto, Kazuyuki; Shiba, Kazuhiro*; Mori, Hirofumi*; Saji, Hideo*
no journal, ,
no abstracts in English
Ogawa, Kazuma*; Mukai, Takahiro*; Kawai, Keiichi*; Takamura, Norito*; Hanaoka, Hirofumi*; Hashimoto, Kazuyuki; Saji, Hideo*
no journal, ,
Previously, based on the concept of bifunctional radiopharmaceuticals, we developed a highly stableRe-MAG3 complex conjugated bisphosphonate (Re-MAG3-HBP) for treatment of the painful bone metastases. We assumed that competitive inhibitors of protein binding might be useful forRe-MAG3-HBP because it has been reported that the concurrent administration between 
Tc-MAG3 and drugs with high protein binding affinity produced competitive displacement at the specific binding sites and enhanced total clearance and tissue distribution. In this study, the displacement effect between Re-MAG3-HBP and several protein binding inhibitors were investigated. Effects of each competitive protein binding inhibitor were examined in in vitro human serum. Bucolome, ceftriaxione and cefazolin as displacers of human serum albumin (HSA) binding site I, and ibuprofen as a displacer of HSA binding site II were added to each serum before addition of Re-MAG3-HBP. As a result of in vitro study, the free fraction rate of Re-MAG3-HBP was significantly increased by the addition of ceftriaxone. In biodistribution studies, the loading ceftriaxone enhanced the clearance of radioactivity of Re-MAG3-HBP in blood and non-target tissues without the reduction of the bone accumulation. These findings suggested that the use of a protein binding competitive inhibitor would be effective for lowering the side effects of Re-MAG3-HBP.
Re-labeled antibody (A7) by a simple method using rhenium(I) tricarbonyl complexOgawa, Kazuma*; Kawashima, Hidekazu*; Kinuya, Seigo*; Yoshimoto, Mitsuyoshi*; Shiba, Kazuhiro*; Kimura, Hiroyuki*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*
no journal, ,
Re is one of the most useful radionuclides for internal radiotherapy. However, there is a problem when protein such as antibody is used as a carrier of Re. The labeling method using bifunctional chelating agents require the conjugation of Re-complex to protein after radiolabeling with the bifunctional chelating agent. Then, we planned the preparation of a stable Re-labeled protein by a simple method. A7 monoclonal antibody was labeled by reacting Re(I) tricarbonyl precursor with A7 directly. Re labeled A7 was prepared with radiochemical yield of 23%. After purification, Re labeled A7 showed radiochemical purity over 98%. After 24 hours of incubation, about 93% of Re-A7 remained intact, which indicates Re-A7 is stable in vitro. In biodistribution experiment, 11.2% of the injected dose/g of Re-A7 accumulated in the tumor at 24 hours postinjection, and tumor to blood ratio was over 1.0 at the same time.
Watanabe, Satoshi; Hashimoto, Kazuyuki; Watanabe, Shigeki; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko
no journal, ,
no abstracts in English
Yokobori, Shinichi*; Yang, Y.*; Fujisaki, Kenta*; Kawaguchi, Yuko*; Kobayashi, Kensei*; Hashimoto, Hirofumi*; Kawai, Hideyuki*; Mita, Hajime*; Narumi, Issei; Okudaira, Kyoko*; et al.
no journal, ,
no abstracts in English
